Nalaganje...
Belimumab for systemic lupus erythematosus
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...
Shranjeno v:
| izdano v: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Ltd
2021
|
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/ https://ncbi.nlm.nih.gov/pubmed/33631841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|